Steven Mennona, MD
Orthopaedic Trauma · Manasquan, NJNPI 1588014997
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Smith+Nephew accounts for 67.9% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $4,280, 2.3 times the $1,873 reported in 2022.
Across 47 payments — averaging $168.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$5K
- Stryker$2K
- Davol Inc.$315
- Zimmer Biomet$146
- Innovation Technologies Inc$142
- Intellijoint Surgical Inc.$125
- plus $200 from 4 others
What the payments were for
- Consulting fees$3,60945%
- Travel & lodging$1,41218%
- Food & beverage$2,91337%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 8 | $5,384 |
| Stryker | 28 | $1,622 |
| Davol Inc. | 2 | $315 |
| Zimmer Biomet | 1 | $146 |
| Innovation Technologies Inc | 1 | $142 |
| Intellijoint Surgical Inc. | 1 | $125 |
| Curvafix, Inc. | 1 | $114 |
| Medacta USA, Inc. | 1 | $43 |
| Heraeus Medical, LLC. | 3 | $29 |
| Seapearl East, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Journey II$13,846
- Journey II XR$5,057
- REAL INTELLIGENCE$4,058
- ACCOLADE$448
- MAKO$418
- TRIATHLON$337
- Legion Revision$180
- Persona$146
- Irrisept$142
- ORTHOLOC 2 LAPIFUSE$128
- Intellijoint HIP$125
- CurvaFix IM Implant$114
How this compares
Too few orthopaedic trauma providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 615 | $1,504 |
| Methylprednisolone | 159 | $1,053 |
| Celecoxib | 32 | $354 |
| Amoxicillin | 39 | $77 |
| Oxycodone Hcl | 15 | $46 |
| Tramadol Hcl | 15 | $42 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic trauma in Manasquan
- Frank LiporaceJersey City$3.6M
- Mark ReillyNewark$540K
- Milan SenClifton$152K
- Mark AdamsNewark$38K
- Julie KellerMaywood$29K
- Joseph GallowayNewark$15K
- Richard SchenkWhippany$10K
- Sergio PulidoMoorestown$10K
- David HamptonMedford$9K
- Jason SchneidkrautWayne$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.